Neoadjuvant Immunotherapy with Nivolumab, Ipilimumab, MDNA11, and Tocilizumab in High-Risk Resectable Melanoma: A Phase Ib Multicentre Randomised Trial

The primary objective of this study is to evaluate the efficacy of **neoadjuvant immunotherapy** combinations in patients with **high-risk, surgically resectable melanoma**. This involves assessing the therapeutic potential of Nivolumab alone or in combination with Ipilimumab, as well as the IL-2 Superkine MDNA11 alone or with Tocilizumab. The clinical relevance of this study lies in its potential to improve treatment outcomes for patients with this aggressive form of melanoma, potentially enhancing surgical resectability and reducing recurrence rates.

The clinical trial involves participants diagnosed with **high-risk, surgically resectable melanoma**. The study population includes both male and female subjects, encompassing a broad age range from adolescents to adults. The trial specifically includes vulnerable populations, although the exact number of participants has not been disclosed by the sponsor. Participants were selected based on criteria that ensure the inclusion of individuals who can provide relevant data for the study, although specific inclusion or exclusion criteria have not been detailed. Lifestyle factors such as diet, physical activity, or habits have not been specified in the available data.

The clinical trial is designed as a **randomized**, double-blind, controlled study to evaluate the efficacy and safety of neoadjuvant immunotherapy combinations in patients with **high-risk, surgically resectable melanoma**. The trial is categorized as a Phase 3 study and is expected to commence recruitment on September 2, 2025, with an estimated completion date of September 2, 2031. Participants will be randomly assigned to receive either nivolumab alone or in combination with ipilimumab, alongside the IL-2 superkine MDNA11, with or without tocilizumab. The trial aims to assess the therapeutic potential of these combinations in reducing tumor burden prior to surgical resection.

The study will include several key visits, beginning with an inclusion (screening) visit to determine participant eligibility based on predefined criteria. Following successful screening, participants will undergo baseline assessments before the initiation of treatment. Throughout the trial, regular follow-up visits will be scheduled to monitor the participants' response to treatment, assess any adverse events, and ensure compliance with the study protocol. The end-of-study visit will occur after the final treatment cycle, where comprehensive evaluations will be conducted to gather data on the primary and secondary endpoints.

Participant involvement in the trial is expected to last until the end-of-study visit, contingent upon adherence to the study protocol and absence of any conditions warranting early termination. Conditions that may lead to early withdrawal include significant adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design ensures rigorous monitoring and data collection to support the evaluation of the investigational treatments' safety and efficacy in the target population.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments, including their names, dosages, or administration routes. The trial documentation does not specify any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on September 2, 2025, with an estimated completion date of September 2, 2031. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the accurate collection and analysis of efficacy data. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy outcomes.